1.Deng S, Zhang Y, Wang H, Liang W, Xie L, Li N, Fang Y, Wang Y, Liu J, Chi H, Sun Y, Ye R, Shan L, Shi J, Shen Z, Wang Y, Wang S, Brosseau JP, Wang F, Liu G, Quan Y, Xu J*, ITPRIPL1 binds CD3ε to impede T-cell activation and enable tumor immune evasion. Cell, 2024 Apr 5:S0092-8674(24)00310-6

2.Wang Y, Sun Y, Deng S, Liu J, Yu J, Chi H, Han X, Zhang Y, Shi J, Wang Y, Quan Y, Li H, Xu J*,Discovery of galectin-8 as an LILRB4 ligand driving M-MDSCs defines a class of antibodies to fight solid tumors. Cell Reports Medicine, 2024,5(1):101374

3.Wang H, Yao H, Li C, Shi H, Lan J, Li Z, Zhang Y, Liang L, Fang JY, Xu J*, HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nature Chemical Biology, 2019 (1): 42~50. 

4.Yao H, Lan J, Li C, Shi H, Brosseau JP, Wang H, Lu H, Fang C, Zhang Y, Liang L, Zhou X, Wang C, Xue Y, Cui Y, Xu J*, Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours, Nature Biomedical Engineering，2019; 3(5):414.

5.Li C, Chi H, Deng S, Xu K, Wang H, Yao H, Wang Y, Chen D, Guo X, Fang JY, He F, Xu J^(*). THADA drives Golgi residency and upregulation of PD-L1 in cancer cells and provides promising target for immunotherapy. J Immunother Cancer. 2021 Aug;9(8):e002443.

6.Liang L, Wang H, Shi H, Li Z, Yao H, Bu Z, Song N, Li C, Xiang D, Zhang Y, Wang J, Hu Y, Xu Q, Ma Y, Cheng Z, Wang Y, Zhao S, Qian J, Chen Y, Fang JY, Xu, J*, A Designed Peptide Targets Two Types of Modifications of p53 with Anti-cancer Activity, Cell Chemical Biology, 2018, 25(6): 761~774

7.Li C, Yao H, Wang H, Fang JY, Xu J*, Repurposing screen identifies Amlodipine as an inducer of PD-L1 degradation and antitumor immunity. Oncogene. 2020. DOI: 10.1038/s41388-020-01592-6

8.Xu, J*. (2020). Regulation of Cancer Immune Checkpoints. Springer Nature. Hardcover book, ISBN: 9811532656. Pages 1-653. (*Book Editor)